Source comparison
Tesamorelin vs Synthetic GH vs Other GHRH Analogues: Clinical Comparison
Before choosing a protocol, understand what differentiates tesamorelin from alternatives. Tesamorelin (Egrifta) GHRH receptor agonist. Stimulates endogenous GH pulsatile release 11.3% (COSMIX trial) Moderate (+40–60 ng/mL) Low. Preserves feedback regulation Fi
This comparison does not assign a generated winner or score.
- Before choosing a protocol, understand what differentiates tesamorelin from alternatives.
- Tesamorelin (Egrifta)
- GHRH receptor agonist. Stimulates endogenous GH pulsatile release
- 11.3% (COSMIX trial)
- Moderate (+40–60 ng/mL)
- Low. Preserves feedback regulation
- First-line for visceral adiposity in metabolic dysfunction; minimal pituitary suppression risk
- Synthetic GH (Somatropin)
- Direct GH replacement. Bypasses hypothalamic-pituitary axis
- 8–12% (dosing-dependent)
- High (+80–120 ng/mL)
- High. Sustained hyperglycemia documented in 15–20% of users
- Effective but carries acromegaly risk; pituitary shutdown common with prolonged use
- Sermorelin (GRF 1-29)
- GHRH analogue. Shorter half-life than tesamorelin
- 5–7% (limited trial data)
- Low to moderate (+20–40 ng/mL)
- Low
- Requires multiple daily injections; DPP-4 degradation limits efficacy
- CJC-1295 (modified GHRH)
- GHRH analogue with drug affinity complex extension
- 9–11% (observational studies only)
- Moderate to high (+50–90 ng/mL)
- Moderate. Prolonged GH elevation may impair glucose tolerance
- No FDA approval; long half-life (5–8 days) complicates dose titration
- Ipamorelin (ghrelin mimetic)
- Growth hormone secretagogue receptor agonist
- 3–5% (minimal visceral selectivity)
- Low (+15–30 ng/mL)
- Very low
- Poor visceral fat specificity; better suited for lean mass preservation
- Tesamorelin sits at the intersection of efficacy and safety. It delivers clinically meaningful visceral fat reduction without the metabolic side effects that limit synthetic GH use. The trade-off is cost: tesamorelin runs $3,000–$4,500 monthly at retail pricing for brand-name Egrifta, versus $800–$1,500 for compounded alternatives through licensed 503B facilities. Compounded tesamorelin contains the same 44-amino-acid sequence but lacks FDA batch-level oversight. The active molecule is identical, but purity verification is the buyer's responsibility.